UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 10, 2021
 
 
THE BEAUTY HEALTH COMPANY
(Exact name of registrant as specified in its charter)
 
 
Delaware   001-39565   85-1908962
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2165 Spring Street
Long Beach, CA
(Address of principal executive offices)

90806
(Zip Code)
(800) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class  
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001 per share   SKIN   The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Class A Common Stock at a price of $11.50   SKINW   The Nasdaq Stock Market LLC



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    
 



Item 7.01 Regulation FD Disclosure.

As previously disclosed, The Beauty Health Company (the “Company”) is conducting investor meetings and presenting virtually at the Goldman Sachs Annual Global Healthcare Conference at 3:00 p.m. Eastern time on June 10, 2021. The Company intends to make reference to an investor presentation containing certain information and financial highlights during such conference and at the Jefferies Virtual Consumer Conference at 4:25 p.m. Eastern time on June 22, 2021. A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the investor presentation and live webcasts of the presentations are, and an archived replays of the webcasts will be, available on the investor relations section of the Company’s website at https://investors.beautyhealth.com.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of the Exchange Act, or otherwise subject to the liabilities of the Exchange Act of 1934 (the “Exchange Act”), nor shall it be incorporated by reference into a filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.

Description
99.1*


* Furnished herewith.



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: June 10, 2021 The Beauty Health Company
By: /s/ Liyuan Woo
Name: Liyuan Woo
Title: Chief Financial Officer
 


Vesper Healthcare Acquis... (NASDAQ:VSPR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vesper Healthcare Acquis... Charts.
Vesper Healthcare Acquis... (NASDAQ:VSPR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vesper Healthcare Acquis... Charts.